[HTML][HTML] Comparison of clinical outcomes following gefitinib and erlotinib treatment in non–small-cell lung cancer patients harboring an epidermal growth factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - Elsevier
… Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal growth factor
… We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring …
… We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring …
[HTML][HTML] … of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study …
K Hotta, K Kiura, N Takigawa, H Yoshioka… - Journal of Thoracic …, 2010 - Elsevier
… incidence of ILD in the current cohort study (Table 3). A previous Japanese study also
showed a higher incidence of ILD emergence during gefitinib therapy in patients with a poor PS (…
showed a higher incidence of ILD emergence during gefitinib therapy in patients with a poor PS (…
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials
L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - Elsevier
… Our search yielded a total of 496 potentially relevant studies with gefitinib or erlotinib. The …
Our study has shown that small-molecule EGFR TKIs gefitinib and erlotinib are associated with …
Our study has shown that small-molecule EGFR TKIs gefitinib and erlotinib are associated with …
First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
… The slightly higher T790M yield of both the gefitinib/erlotinib and afatinib groups in the
present study might be related to the addition of a liquid biopsy when a tissue biopsy was …
present study might be related to the addition of a liquid biopsy when a tissue biopsy was …
Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: a retrospective cohort study in Taiwan
YY Hsieh, WT Fang, YW Lo, YH Chen… - International journal of …, 2020 - Wiley Online Library
… This retrospective cohort study was conducted using data from real-world settings. Patients
with stage IIIB and IV NSCLC and first received gefitinib, erlotinib, or afatinib between 2011 …
with stage IIIB and IV NSCLC and first received gefitinib, erlotinib, or afatinib between 2011 …
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Y Jiang, J Zhang, J Huang, B Xu, N Li, L Cao… - BMC Pulmonary …, 2018 - Springer
… The purpose of this study was to compare clinical outcomes of Erlotinib versus Gefitinib
in the treatment of Asian patients … The cohort consisted of 227 Asian patients (erlotinib-treated …
in the treatment of Asian patients … The cohort consisted of 227 Asian patients (erlotinib-treated …
Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non–small-cell lung cancer
RGP Gijtenbeek, RAM Damhuis, HJM Groen… - Clinical lung cancer, 2020 - Elsevier
… erlotinib, we observed a poorer adjusted survival for gefitinib … , this study is the largest
European real-world cohort of … erlotinib, we observed a poorer adjusted survival for gefitinib …
European real-world cohort of … erlotinib, we observed a poorer adjusted survival for gefitinib …
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
CH Lee, MC Shen, MJ Tsai, JS Chang, YB Huang… - Scientific Reports, 2022 - nature.com
… -based cohort study demonstrated that concurrent PPI with gefitinib or erlotinib was
associated with significantly poorer OS and TTNT than the H2RA and non-user. Other studies …
associated with significantly poorer OS and TTNT than the H2RA and non-user. Other studies …
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR …
S Heon, BY Yeap, NI Lindeman, VA Joshi… - … Cancer Research, 2012 - AACR
… CNS failure in patients with NSCLC treated with gefitinib or erlotinib (17, 32). Investigating
… our study, the risk of CNS progression was not independently examined in a NSCLC cohort …
… our study, the risk of CNS progression was not independently examined in a NSCLC cohort …
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study
… Gefitinib and erlotinib are tyrosine kinase inhibitors (TKIs) specific for the epidermal growth
factor receptor (EGFR). The response rate to TKIs was significantly high in NSCLC patients of …
factor receptor (EGFR). The response rate to TKIs was significantly high in NSCLC patients of …